Publication | Closed Access

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

MedicinePathologyFirst-line TreatmentHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation Oncology